SEO URLwww.firestrike.ai/deals/ventyx-biosciences-lilly-acquisition-2026-7
acquisitionAnnounced · Jan 10, 2026PharmaceuticalsSource · AdvertisementsArticle · Factual
Lilly acquires Ventyx Biosciences
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$1B
Target
Ventyx Biosciences
NASDAQ: VTYX · San Diego, California
Acquirer
Lilly
Full Acquisition
Status
Announced
Lilly agreed to acquire Ventyx Biosciences. Reported deal value: $1B. Status: Announced. Sector: Pharmaceuticals. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-10. Figures and status may change as filings and press coverage update.
Eli Lilly and Company announced on January 7 that it entered into a definitive agreement to acquire Ventyx Biosciences , Inc. , which is a clinical-stage biopharmaceutical company that develops innovative oral therapies for patients with inflammatory-mediated diseases
Deal timeline
Announced
Jan 10, 2026 · insidermonkey.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $1B. Figures and status may change as sources update.
Sources: insidermonkey.com · Primary article · FireStrike proprietary index